Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CV industry veteran succeeds Howlett as Lombard CEO

This article was originally published in Clinica

Executive Summary

John Rush, a medical device industry veteran with particular experience in the cardiovascular sector, has succeeded Brian Howlett as CEO of UK stent graft developer Lombard Medical Technologies. Mr Rush, a US national, spent 10 years at SciMed Life Systems (which was bought by Boston Scientific in 1994) in various senior sales and marketing and management roles. He has been president and CEO of several small-cap companies, most recently at North American Scientific (NAS), where he led the firm's reorganisation and financial recovery. Mr Rush is expected to take Lombard through the next growth phase, as it expands commercialisation in Europe and secures FDA approval for its flagship Aorfix device. His predecessor, Mr Howlett, will be retiring after nearly four years at Lombard's helm, but will remain with the London firm as executive director until the end of March 2010 to oversee the transition.

You may also be interested in...

Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?

Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.

Roche Dx' EMEA Head To Take Charge After Diggelmann Departs

Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.

Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio

Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts